Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Omnicell to buy Aesynt from Francisco Partners for $275m

Omnicell has signed an agreement to acquire medication management firm Aesynt from Francisco Partners, for around $275m.

Aesynt

Based in Cranberry Township of Pennsylvania, Aesynt provides Intravenous (IV) solutions, central pharmacy solutions, point of care solutions and enterprise software to the healthcare organizations.

With expected annual revenues of about $650m, the combined company will serve around 4,000 acute care facilities across the globe.

The acquired business will expand Omnicell’s product portfolio, with the addition of automated dispensing systems, central pharmacy robotics, IV robotics and enterprise analytics.

Omnicell chairman, president and CEO Randall Lipps said: "As hospitals search for ways to provide the best patient care and also the most efficient care, customers are looking for solutions that can be scaled and customized to fit the unique needs of their health system."

Aesynt provides full suite of automated and semi-automated solutions for the IV room, including hazardous and non-hazardous solutions with IV workflow, compounding software and IV preparation analytics.

The firm’s central pharmacy solutions include unit dose medication dispensing robots, vertical storage and dispensing of medications, open shelf inventory tracking and unit dose repackaging products and services.

Aesynt also offers medication storage and dispensing cabinets for nursing units and operating rooms and narcotic medication storage and dispensing.

In addition, the firm provides enterprise-wide medication logistics management software, automated procurement and order management, and reporting and analytics for inventory management and medication utilization.

Francisco Partners partner and Aesynt directors board chairman Chris Adams said: "Through significant investment in new products -particularly new enterprise medication management software – the team significantly revitalized the organization and returned it to rapid growth."

Subject to customary closing conditions, the deal is expected to be completed in 2016.


Image: Omnicell to acquire medication management firm Aesynt from Francisco Partners. Photo: courtesy of PinkBlue/ FreeDigitalPhotos.net.